Last reviewed · How we verify

A Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms of Multiple Individually Titrated Doses of Radiprodil in Children with GRIN-related Disorder

NCT05818943 Phase 1 ACTIVE_NOT_RECRUITING

Study RAD-GRIN-101 is a phase 1B trial to assess safety, tolerability, PK, and potential efficacy of radiprodil for the treatment of GRIN-related disorder in children with a Gain-of-Function (GoF) genetic variant. The study is open-label, so all participants will be treated with radiprodil. Subjects' participation in the study is expected to last up to six months in Part A. After the end of part A, all participants who are still eligible can choose to continue to receive radiprodil as part of an open-label long-term treatment period (Part B).

Details

Lead sponsorGRIN Therapeutics, Inc.
PhasePhase 1
StatusACTIVE_NOT_RECRUITING
Enrolment24
Start date2023-03-07
Completion2026-11

Conditions

Interventions

Primary outcomes

Countries

United States, Australia, Canada, Germany, Italy, Netherlands, Spain, United Kingdom